Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

about

Natalizumab in Multiple Sclerosis: Long-Term Management.Disease activity return after natalizumab cessation in multiple sclerosis.Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

P2860

Q33754882-B91B8943-C7E5-423A-ABB6-652D310B3691 Q38779091-BAD87FA1-E0E3-4D10-89B8-A0C774C513B9 Q39391443-B964E6B7-229E-45AB-94FC-880F9F4CC30F

P2860

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Item

http://www.wikidata.org/entity/Q48260043

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Randomised natalizumab discont ...... prevent disease reactivation.

@en

Randomised natalizumab discont ...... prevent disease reactivation.

@nl

type

Item

label

Randomised natalizumab discont ...... prevent disease reactivation.

@en

Randomised natalizumab discont ...... prevent disease reactivation.

@nl

prefLabel

Randomised natalizumab discont ...... prevent disease reactivation.

@en

Randomised natalizumab discont ...... prevent disease reactivation.

@nl

P1476

Randomised natalizumab discont ...... prevent disease reactivation.

@en

P2093

David Hojnacki

http://www.w3.org/2001/XMLSchema#string

Deepa P Ramasamy

http://www.w3.org/2001/XMLSchema#string

Ellen Carl

http://www.w3.org/2001/XMLSchema#string

Jesper Hagemeier

http://www.w3.org/2001/XMLSchema#string

Kara Patrick

http://www.w3.org/2001/XMLSchema#string

Katelyn S Kavak

http://www.w3.org/2001/XMLSchema#string

Muhammad Nadeem

http://www.w3.org/2001/XMLSchema#string

Vasu Saini

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

P304

937-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2015-312221

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bianca Weinstock-Guttman

Robert Zivadinov

P577

2016-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291138495

http://www.w3.org/2001/XMLSchema#string

P698

26780938

http://www.w3.org/2001/XMLSchema#string

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

about

P2860

P2860

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698